Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR.

Pediatr Infect Dis J. 1996 Aug;15(8):650-4.

PMID:
8858666
2.

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.

J Infect Dis. 1995 May;171(5):1107-14.

PMID:
7751684
3.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
4.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al.

J Infect Dis. 1995 Dec;172(6):1445-50.

PMID:
7594701
5.

Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age.

Karron RA, Steinhoff MC, Subbarao EK, Wilson MH, Macleod K, Clements ML, Fries LF, Murphy BR.

Pediatr Infect Dis J. 1995 Jan;14(1):10-6.

PMID:
7715982
6.

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.

Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM.

J Infect Dis. 2005 Apr 1;191(7):1116-22. Epub 2005 Feb 22.

PMID:
15747247
7.

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM.

J Infect Dis. 2001 Oct 1;184(7):909-13. Epub 2001 Aug 15.

PMID:
11509996
8.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

PMID:
14745704
9.

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants.

Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ.

Vaccine. 2001 Sep 14;19(32):4676-84.

PMID:
11535316
10.

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.

Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, Hackell J, Paradiso PR, Siber G, Kohberger R, Madore DV, Malinowski FJ, Kimura A, Le C, Landaw I, Aguilar J, Hansen J.

Pediatr Infect Dis J. 1999 Sep;18(9):757-63.

PMID:
10493334
11.

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.

Pennathur S, Haller AA, MacPhail M, Rizzi T, Kaderi S, Fernandes F, Bicha L, Schickli JH, Tang RS, Chen W, Nguyen N, Mathie S, Mehta H, Coelingh KL.

J Gen Virol. 2003 Dec;84(Pt 12):3253-61.

PMID:
14645907
12.

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.

Hurwitz JL, Soike KF, Sangster MY, Portner A, Sealy RE, Dawson DH, Coleclough C.

Vaccine. 1997 Apr;15(5):533-40.

PMID:
9160521
13.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

14.

Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.

Nachman S, Kim S, King J, Abrams EJ, Margolis D, Petru A, Shearer W, Smith E, Moye J, Blanchard S, Hawkins E, Bouquin P, Vink P, Benson M, Estep S, Malinoski F; Pediatric AIDS Clinical Trials Group Study 292 Team.

Pediatrics. 2003 Jul;112(1 Pt 1):66-73.

PMID:
12837869
15.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103. Epub 2004 Nov 8.

PMID:
15551207
16.

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF.

Vaccine. 2006 Mar 20;24(13):2432-9. Epub 2005 Dec 20.

PMID:
16406170
17.

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.

Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, Larson S, Coelingh KL, Mendelman PM.

Vaccine. 2003 Mar 7;21(11-12):1224-31.

PMID:
12559802
18.

Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center.

Clements ML, Makhene MK, Karron RA, Murphy BR, Steinhoff MC, Subbarao K, Wilson MH, Wright PF.

J Infect Dis. 1996 Jan;173(1):44-51.

PMID:
8537681
19.

Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants.

Maldonado Y, Hestvik L, Wilson M, Townsend T, O'Hare J, Wee S, Yolken R.

J Pediatr. 1986 Dec;109(6):931-5.

PMID:
3537248
20.

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.

Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S6-S16.

PMID:
16088807

Supplemental Content

Support Center